Aktienanalyse zu Daxor Corp (DXR)DXRDaxor Corp

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense. It operates in the Financials sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Daxor Corp is not a good buy right now due to its current price of 9.00, which is significantly lower than its 52-week high of 14.76 and reflects a year-to-date decline of 37.33%. The RSI is at 31.488, indicating that the stock is oversold, but the forward P/E ratio is high at 64.5161, suggesting that the stock may be overvalued despite recent revenue growth of 45% year-over-year. The main risk is the stock's performance decline of 37.33% year-to-date, indicating ongoing weakness in market sentiment.